{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30287840", "DateCompleted": {"Year": "2019", "Month": "11", "Day": "13"}, "DateRevised": {"Year": "2024", "Month": "04", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "10", "Day": "04"}], "Language": ["eng"], "ELocationID": ["1025", "10.1038/s41419-018-1038-3"], "Journal": {"ISSN": "2041-4889", "JournalIssue": {"Volume": "9", "Issue": "10", "PubDate": {"Year": "2018", "Month": "Oct", "Day": "04"}}, "Title": "Cell death & disease", "ISOAbbreviation": "Cell Death Dis"}, "ArticleTitle": "Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1\u03b1 and induces DNA damage by sequestering ferrous iron.", "Pagination": {"StartPage": "1025", "MedlinePgn": "1025"}, "Abstract": {"AbstractText": ["Procaspase-3-activating compound 1 (PAC-1) induces procaspase-3 activation via zinc chelation. However, whether PAC-1 employs other mechanisms remains unknown. Here we systematically screened for potent PAC-1 targets using 29 enhanced green fluorescent protein-labeled reporter cell lines and identified hypoxia-inducible factor 1\u03b1 (HIF1\u03b1) and RAD51 pathways as PAC-1 targets. These results were verified in HepG2 cells and two other cancer cell lines. Mechanistically, PAC-1 specifically blocked HIF1\u03b1 hydroxylation and upregulated HIF1\u03b1 target genes. In addition, DNA damage, G<sub>1</sub>/S cell cycle arrest, and the inhibition of DNA synthesis were induced following PAC-1 administration. Interestingly, by using ferrozine-iron sequestration and iron titration assays, we uncovered the iron sequestering capacity of PAC-1. Additionally, the expression levels of iron shortage-related genes were also increased in PAC-1-treated cells, and iron (II) supplementation reversed all of the observed cellular responses. Thus, our results indicate that PAC-1 induces HIF1\u03b1 stabilization and DNA damage by sequestering ferrous iron."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, 100850, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Cell Proliferation and Regulation Biology, Beijing Normal University, Beijing, 100875, China."}], "LastName": "Li", "ForeName": "Feifei", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, 100850, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Cell Proliferation and Regulation Biology, Beijing Normal University, Beijing, 100875, China."}], "LastName": "Wei", "ForeName": "Aili", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, 100850, China."}], "LastName": "Bu", "ForeName": "Lijuan", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, 100850, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}], "LastName": "Long", "ForeName": "Long", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, 100850, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}], "LastName": "Chen", "ForeName": "Wei", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, 100850, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Cell Proliferation and Regulation Biology, Beijing Normal University, Beijing, 100875, China."}], "LastName": "Wang", "ForeName": "Chen", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Cell Proliferation and Regulation Biology, Beijing Normal University, Beijing, 100875, China. 04020@bnu.edu.cn."}], "LastName": "Zhao", "ForeName": "Changqi", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, 100850, China. wangll63@126.com."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China. wangll63@126.com."}], "LastName": "Wang", "ForeName": "Lili", "Initials": "L"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Cell Death Dis", "NlmUniqueID": "101524092"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "(4-benzylpiperazin-1-yl)acetic acid (3-allyl-2-hydroxybenzylidene)hydrazine"}, {"RegistryNumber": "0", "NameOfSubstance": "Hydrazones"}, {"RegistryNumber": "0", "NameOfSubstance": "Hypoxia-Inducible Factor 1, alpha Subunit"}, {"RegistryNumber": "0", "NameOfSubstance": "Piperazines"}, {"RegistryNumber": "28048-33-1", "NameOfSubstance": "Ferrozine"}, {"RegistryNumber": "E1UOL152H7", "NameOfSubstance": "Iron"}, {"RegistryNumber": "EC 2.7.7.-", "NameOfSubstance": "Rad51 Recombinase"}, {"RegistryNumber": "EC 3.4.22.-", "NameOfSubstance": "Caspase 3"}, {"RegistryNumber": "J41CSQ7QDS", "NameOfSubstance": "Zinc"}], "MeshHeadingList": [{"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["metabolism"], "DescriptorName": "Caspase 3"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Cycle Checkpoints"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "DNA Damage"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Ferrozine"}, {"QualifierName": ["drug effects"], "DescriptorName": "G1 Phase Cell Cycle Checkpoints"}, {"QualifierName": [], "DescriptorName": "Hep G2 Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Hydrazones"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Hypoxia"}, {"QualifierName": ["metabolism"], "DescriptorName": "Hypoxia-Inducible Factor 1, alpha Subunit"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Iron"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Piperazines"}, {"QualifierName": ["metabolism"], "DescriptorName": "Rad51 Recombinase"}, {"QualifierName": ["drug effects"], "DescriptorName": "Up-Regulation"}, {"QualifierName": ["metabolism"], "DescriptorName": "Zinc"}], "CoiStatement": "The authors declare that they have no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21:485\u2013495. doi: 10.1093/carcin/21.3.485.", "ArticleIdList": ["10.1093/carcin/21.3.485", "10688869"]}, {"Citation": "Putt KS, et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat. Chem. Biol. 2006;2:543\u2013550. doi: 10.1038/nchembio814.", "ArticleIdList": ["10.1038/nchembio814", "16936720"]}, {"Citation": "Hsu DC, et al. Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1) ACS Comb. Sci. 2012;14:44\u201350. doi: 10.1021/co2001372.", "ArticleIdList": ["10.1021/co2001372", "PMC3253983", "22007686"]}, {"Citation": "Peterson QP, et al. Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound. Cancer Res. 2010;70:7232\u20137241. doi: 10.1158/0008-5472.CAN-10-0766.", "ArticleIdList": ["10.1158/0008-5472.CAN-10-0766", "PMC3113694", "20823163"]}, {"Citation": "Wolan DW, Zorn JA, Gray DC, Wells JA. Small-molecule activators of a proenzyme. Science. 2009;326:853\u2013858. doi: 10.1126/science.1177585.", "ArticleIdList": ["10.1126/science.1177585", "PMC2886848", "19892984"]}, {"Citation": "Wang F, et al. A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts. Mol. Oncol. 2014;8:1640\u20131652. doi: 10.1016/j.molonc.2014.06.015.", "ArticleIdList": ["10.1016/j.molonc.2014.06.015", "PMC5528581", "25053517"]}, {"Citation": "Strand OA, et al. Synthesis and initial in vitro biological evaluation of two new zinc-chelating compounds: comparison with TPEN and PAC-1. Bioorg. Med. Chem. 2013;21:5175\u20135181. doi: 10.1016/j.bmc.2013.06.037.", "ArticleIdList": ["10.1016/j.bmc.2013.06.037", "23859779"]}, {"Citation": "Denault JB, et al. Small molecules not direct activators of caspases. Nat. Chem. Biol. 2007;3:519. doi: 10.1038/nchembio0907-519.", "ArticleIdList": ["10.1038/nchembio0907-519", "17710090"]}, {"Citation": "Peterson QP, et al. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J. Mol. Biol. 2009;388:144\u2013158. doi: 10.1016/j.jmb.2009.03.003.", "ArticleIdList": ["10.1016/j.jmb.2009.03.003", "PMC2714579", "19281821"]}, {"Citation": "Long L, et al. Dynamic cytotoxic profiles of sulfur mustard in human dermal cells determined with multiparametric high-content analysis. Toxicol. Res. 2016;5:583\u2013593. doi: 10.1039/C5TX00305A.", "ArticleIdList": ["10.1039/C5TX00305A", "PMC6062398", "30090372"]}, {"Citation": "Wang C, Wang L, Zhao C. Development of a plate-based assay for high-content analysis of individual untethered non-adherent cells. Comb. Chem. High Throughput Screen. 2011;14:583\u2013589. doi: 10.2174/138620711796367247.", "ArticleIdList": ["10.2174/138620711796367247", "21534915"]}, {"Citation": "Meng J, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS ONE. 2010;5:e14124. doi: 10.1371/journal.pone.0014124.", "ArticleIdList": ["10.1371/journal.pone.0014124", "PMC2993951", "21124782"]}, {"Citation": "Chen W, et al. Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster. PLoS ONE. 2014;9:e96056. doi: 10.1371/journal.pone.0096056.", "ArticleIdList": ["10.1371/journal.pone.0096056", "PMC3997506", "24759758"]}, {"Citation": "Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci. STKE. 2005;2005:re12.", "ArticleIdList": ["16234508"]}, {"Citation": "Bonner WM, et al. GammaH2AX and cancer. Nat. Rev. Cancer. 2008;8:957\u2013967. doi: 10.1038/nrc2523.", "ArticleIdList": ["10.1038/nrc2523", "PMC3094856", "19005492"]}, {"Citation": "To KK, Huang LE. Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J. Biol. Chem. 2005;280:38102\u201338107. doi: 10.1074/jbc.M504342200.", "ArticleIdList": ["10.1074/jbc.M504342200", "PMC1307502", "16157596"]}, {"Citation": "Jeong JB, De Lumen BO, Jeong HJ. Lunasin peptide purified from Solanum nigrum L. protects DNA from oxidative damage by suppressing the generation of hydroxyl radical via blocking fenton reaction. Cancer Lett. 2010;293:58\u201364. doi: 10.1016/j.canlet.2009.12.019.", "ArticleIdList": ["10.1016/j.canlet.2009.12.019", "20083341"]}, {"Citation": "Bowes J, et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 2012;11:909\u2013922. doi: 10.1038/nrd3845.", "ArticleIdList": ["10.1038/nrd3845", "23197038"]}, {"Citation": "Dahlin JL, Nelson KM. Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors. Nat. Commun. 2017;8:1527. doi: 10.1038/s41467-017-01657-3.", "ArticleIdList": ["10.1038/s41467-017-01657-3", "PMC5688144", "29142305"]}, {"Citation": "Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci. STKE. 2007;2007:cm8. doi: 10.1126/stke.4072007cm8.", "ArticleIdList": ["10.1126/stke.4072007cm8", "17925579"]}, {"Citation": "Masson N, Ratcliffe PJ. HIF prolyl and asparaginyl hydroxylases in the biological response tointracellular O2 levels. J. Cell Sci. 2003;116:3041. doi: 10.1242/jcs.00655.", "ArticleIdList": ["10.1242/jcs.00655", "12829734"]}, {"Citation": "Mcneill LA, et al. Hypoxia-inducible factor prolyl hydroxylase 2 has a high affinity for ferrous iron and 2-oxoglutarate. Mol. Biosyst. 2005;1:321\u2013324. doi: 10.1039/b511249b.", "ArticleIdList": ["10.1039/b511249b", "16880998"]}, {"Citation": "Ono, S. et al. Effect of Deferoxamine-activated Hypoxia Inducible Factor-1 on the Brainstem Following Subarachnoid Haemorrhage (Springer, Vienna, 2008).", "ArticleIdList": ["18300912"]}, {"Citation": "Baell J, Walters MA. Chemistry: chemical con artists foil drug discovery. Nature. 2014;513:481\u2013483. doi: 10.1038/513481a.", "ArticleIdList": ["10.1038/513481a", "25254460"]}, {"Citation": "Frye SV, et al. Tackling reproducibility in academic preclinical drug discovery. Nat. Rev. Drug Discov. 2015;14:733. doi: 10.1038/nrd4737.", "ArticleIdList": ["10.1038/nrd4737", "26388229"]}, {"Citation": "Peterson QP, et al. Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3. J. Med. Chem. 2009;52:5721\u20135731. doi: 10.1021/jm900722z.", "ArticleIdList": ["10.1021/jm900722z", "PMC2749958", "19708658"]}, {"Citation": "Charkoudian LK, Franz KJ. Fe(III)-coordination properties of neuromelanin components: 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. Inorg. Chem. 2006;45:3657\u20133664. doi: 10.1021/ic060014r.", "ArticleIdList": ["10.1021/ic060014r", "16634598"]}, {"Citation": "Charkoudian LK, Pham DM, Franz KJ. A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J. Am. Chem. Soc. 2006;128:12424\u201312425. doi: 10.1021/ja064806w.", "ArticleIdList": ["10.1021/ja064806w", "16984186"]}, {"Citation": "Gautam R, Akam EA, Astashkin AV, Loughrey JJ, Tomat E. Sirtuin inhibitor sirtinol is an intracellular iron chelator. Chem. Commun. (Camb.). 2015;51:5104\u20135107. doi: 10.1039/C5CC00829H.", "ArticleIdList": ["10.1039/C5CC00829H", "PMC4355247", "25715179"]}, {"Citation": "Choi SM, Choi KO, Lee N, Oh M, Park H. The zinc chelator, N,N,N\u2019,N\u2019-tetrakis (2-pyridylmethyl) ethylenediamine, increases the level of nonfunctional HIF-1alpha protein in normoxic cells. Biochem. Biophys. Res. Commun. 2006;343:1002\u20131008. doi: 10.1016/j.bbrc.2006.03.039.", "ArticleIdList": ["10.1016/j.bbrc.2006.03.039", "16579968"]}, {"Citation": "Cook KM, et al. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J. Biol. Chem. 2009;284:26831\u201326838. doi: 10.1074/jbc.M109.009498.", "ArticleIdList": ["10.1074/jbc.M109.009498", "PMC2785371", "19589782"]}, {"Citation": "Furukawa T, Naitoh Y, Kohno H, Tokunaga R, Taketani S. Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci. 1992;50:2059\u20132065. doi: 10.1016/0024-3205(92)90572-7.", "ArticleIdList": ["10.1016/0024-3205(92)90572-7", "1608289"]}, {"Citation": "Le NTV, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim. Biophys. Acta. 2002;1603:31\u201346.", "ArticleIdList": ["12242109"]}, {"Citation": "Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets. 2006;6:409\u2013431. doi: 10.2174/156800906777723949.", "ArticleIdList": ["10.2174/156800906777723949", "16918309"]}, {"Citation": "Hoyes KP, Hider RC, Porter JB. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res. 1992;52:4591\u20134599.", "ArticleIdList": ["1511427"]}, {"Citation": "El-Chammas Khalil. Book Review: Iron Deficiency and Overload: From Basic Biology to Clinical MedicineYehudaSMostofskyDI (editors). Iron Deficiency and Overload: From Basic Biology to Clinical Medicine. Totowa, NJ: Humana Press; 2010. 371 pp. ISBN 978-1-934115-22-0. Nutrition in Clinical Practice. 2010;25(5):562\u2013562. doi: 10.1177/0884533610379857.", "ArticleIdList": ["10.1177/0884533610379857"]}, {"Citation": "Qin Y, Dittmer PJ, Park JG, Jansen KB, Palmer AE. Measuring steady-state and dynamic endoplasmic reticulum and Golgi Zn2\u2009+\u2009with genetically encoded sensors. Proc. Natl. Acad. Sci. USA. 2011;108:7351\u20137356. doi: 10.1073/pnas.1015686108.", "ArticleIdList": ["10.1073/pnas.1015686108", "PMC3088641", "21502528"]}]}], "History": [{"Year": "2018", "Month": "5", "Day": "10"}, {"Year": "2018", "Month": "9", "Day": "6"}, {"Year": "2018", "Month": "9", "Day": "4"}, {"Year": "2018", "Month": "10", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "11", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "4"}], "PublicationStatus": "epublish", "ArticleIdList": ["30287840", "PMC6172261", "10.1038/s41419-018-1038-3", "10.1038/s41419-018-1038-3"]}}]}